This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral antibiotic in the treatment of community acquired pneumonia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
250
Enanta Pharmaceuticals, Inc.
Watertown, Massachusetts, United States
RECRUITINGClinical Cure 7-14 days after end of therapy
Bacteriological response
Radiographic response
Change in signs and symptoms
Safety
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.